Drug Trial Radar · NCT05988463
Dose-Escalation Study of Artesunate Patients With IPF
Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Aug 1, 2026
Primary completion
Nov 1, 2028
Study completion Nov 1, 2028
Sponsor
- Lead sponsor
- Joseph C. WuAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Idiopathic Pulmonary Fibrosis (IPF) is a chronic progressive fibrotic lung disease resulting in increasing shortness of breath, cough, and low oxygen levels as a result of lung tissue scarring . This will be a single-center randomized, double-blinded, placebo-controlled study of 20 weeks including up to 4 weeks for screening, followed by 12 weeks of oral artesunate treatment across 3 dose levels (dose escalation every 4 weeks), and 4 weeks of a washout (follow-up) period in participants with Idiopathic Pulmonary Fibrosis (IPF). The primary objective of the study is to evaluate the safety and tolerability of artesunate at 3 dose levels, and to select the dose(s) to carry forward into additional clinical testing. The secondary objective includes exploring the blood biomarkers present in participants with IPF at baseline and to investigate how those biomarkers change following artesunate treatment. The exploratory objectives include assessing the changes in the K-BILD and Leicester cough questionnaire scores and change in pulmonary function after artesunate administration.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
ArtesuanteDrug
Artesunate capsules administered orally twice daily beginning at 20 mg for 4 weeks, followed by 40 mg for 4 weeks, and then 60 mg for 4 weeks.
Placebo capsulesOther
Placebo capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants who experience treatment-related adverse eventsTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Stanford University
Stanford, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.